Close menu

February 12th, 2024 | 07:00 CET

MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

  • Biotechnology
  • Pharma
Photo credits:

Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.

time to read: 4 minutes | Author: Armin Schulz

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    MorphoSys - To be acquired

    The rumors about a potential acquisition of MorphoSys have been circulating for a while, especially when the stock fell below the EUR 20 mark. Since the end of October, the share had already started to rebound from its low of EUR 14.52. When the rumors about Novartis emerged, the share price shot up further. Novartis has made shareholders an offer of EUR 68 per share and is thus paying around EUR 2.7 billion for the former German biotech flagship company. For the takeover to proceed, at least 65% of all shares must be tendered to Novartis.

    With this step, Novartis aims to strengthen its portfolio in the field of oncology. MorphoSys has an extensive oncology pipeline. The focus is on developing treatment options for diseases such as myelofibrosis. The question remains as to why the Swiss are willing to pay such a high price. The high premium on the share price could be due to the fact that another interested party, Incyte, has made an effort to acquire MorphoSys. In the end, Incyte secured the global marketing rights for MorphoSys's drug tafasitamab for USD 25 million on February 5. Tafasitamab received accelerated FDA approval for the treatment of diffuse large B-cell lymphoma.

    It can be assumed that the takeover will go ahead. The Board of Directors and the Supervisory Board have voted in favor of the Novartis offer. Should Novartis wish to terminate the agreement, the Company would have to pay EUR 100 million to MorphoSys. Many shareholders were in despair in early October last year, and now the share has gained around 360% from its lows, provided shareholders accept the offer. Last Friday, the share closed at EUR 64.10 in XETRA trading. There is not much room left to reach the EUR 68 offered.

    Defence Therapeutics - AccuTOX® is also effective against lung cancer

    Defence Therapeutics utilizes its patented Accum™ technology to develop novel cancer therapies. It involves using proprietary or third-party antibody-drug conjugates (ADCs) and targeting them to fight cancer cells. Even ADCs that initially failed can be given a second chance with this technology, as the optimized transport increases efficacy by up to 10 times. In some cases, the dosage can also be reduced. The focus is on melanoma, breast cancer, and lung cancer. The Accum™ platform can also be used to develop vaccines against cancer and infectious diseases.

    According to Data Bridge Market Research, the market for solid tumors is expected to reach over USD 900 billion by 2029, indicating high growth potential in this area. In mid-December, Defence Therapeutics received approval from the FDA for a Phase I clinical trial to combat solid cancer tumors with the drug AccuTOX®. This marks a significant advance in immuno-oncology for the Company. The drug stimulates the immune system and inhibits tumor cell growth. On January 10, the Company announced that AccuTOX® has also been successfully tested against tumors in the lung.

    This new formulation expands the scope of AccuTOX® in treating cancer tumors. These studies cost money, and the Company is currently raising CAD 2.25 million through a private placement at CAD 1.50 per share. In addition, each investor receives a warrant with a strike price of CAD 2.00, valid for 24 months. The first tranche was completed at the beginning of February, raising CAD 850,500. The money will be used to finance the studies. After the share price moved towards CAD 1.50 following the announcement of the financing, it subsequently rose to CAD 2.32. One share currently costs CAD 2.00.

    Defence Therapeutics will present at the 10th International Investment Forum

    Bayer - Not just a shadow

    Over the years, Bayer, once a beacon of German engineering and pharmaceutical innovation, has lost much of its luster and is facing challenges. A major factor is the problematic acquisition of Monsanto in 2018, which has left the Company with immense debts and a flood of legal battles. This decision, in retrospect, marked a turning point from which Bayer's image and finances were severely affected. In addition, businesses that were once considered unshakeable are increasingly facing regulatory hurdles, increased competition and shifts in consumer preferences.

    Despite these problems, it is inappropriate to write Bayer off prematurely. After all, the Company still has strengths and potential that point to a positive future. Firstly, there is the strong position in research and development. In Europe, Bayer is leading in patent applications to combat cancer, according to a report from the European Patent Office. The Company is also planning to minimize development times using artificial intelligence. Most recently, a collaboration with TetraScience was announced with the aim of improving the development of active ingredients in all areas.

    The Company is currently undergoing a transformation phase. Jobs are being cut, departments merged and much more to increase efficiency. On March 5, the Company will hold its Capital Markets Day and present its annual figures. It will be interesting to see what the new CEO, Bill Anderson, will present. It will then also become clear whether the dividend will be left untouched. With a current share price of EUR 27.78, this would mean a dividend yield of around 8.6%. However, investors should not count on this with certainty, as many issues need to be resolved that come with associated costs.

    All three companies presented have one thing in common. They are all involved in the fight against cancer. According to experts, this market will grow significantly in the coming years. MorphoSys will most likely be taken over by Novartis. It was important for the Swiss company to secure access to the oncology pipeline. With the Accum™ platform, Defence Therapeutics has created the possibility of transporting active substances directly to diseased cells. With AccuTOX®, the Company has a promising candidate in its portfolio focused on fighting cancer. Bayer has filed the most oncology patents in Europe. The glyphosate lawsuits are currently back in the spotlight. Those not yet invested should wait for March 5 and see if there are any new findings.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Armin Schulz on June 17th, 2024 | 06:30 CEST

    BioNTech, dynaCERT, Plug Power - A single piece of news can change everything

    • Hydrogen
    • greenhydrogen
    • Biotechnology

    Share prices are characterized by their high volatility and can undergo significant changes in a short space of time. Often, just one piece of company news can completely change investor confidence. Shares that were previously under selling pressure and were avoided can suddenly become very popular and experience considerable price increases. Examples include Lufthansa, whose share price rose significantly with the end of the COVID-19 pandemic. Market sentiment can turn quickly when negative factors disappear. A single piece of positive company news can prompt investors to become more involved again, significantly increasing demand and, consequently, the share price. We have identified three potential turnaround candidates.


    Commented by Armin Schulz on June 10th, 2024 | 07:15 CEST

    Evotec, Vidac Pharma, Bayer - Biotech and Pharma: Opportunities for investors

    • Biotechnology
    • Pharma

    In the constantly evolving pharmaceutical and biotechnology industry landscape, innovative strength and strategic orientation play a decisive role in success. Both established groups and young, up-and-coming companies are competing for market share and scientific breakthroughs. In this context, it is worth taking a closer look at Vidac Pharma, Bayer and Evotec. These companies are pursuing different approaches and strategies to achieve their respective goals. How do they manage to hold their own in a highly dynamic market environment, and what prospects are emerging for the future?


    Commented by André Will-Laudien on June 10th, 2024 | 06:45 CEST

    Nasdaq short bets remain dangerous! TUI, Saturn Oil + Gas, Plug Power, and Evotec in the crosshairs

    • Mining
    • Oil
    • renewableenergies
    • Travel
    • Biotechnology

    Last week, Nvidia shares gave the bears a scare. Despite massive price gains in recent months, the shares of the specialist for high-performance chips gained another 20%, adding USD 600 billion to its valuation. Now, behind Microsoft, Nvidia is the second most valuable company in the world, surpassing even Apple. Of course, this did not happen without reason because, as of today, the share is trading at 1:10, which means a tenfold increase in the number of shares in the portfolio for shareholders. This does not change the market value per se, as the share price is also reduced by 90% at the opening. The aim is to make the share more accessible and allow retail investors to get involved. Stock splits of this kind are common on the NASDAQ and have often brought investors additional price gains in the following months. Where are the opportunities for investors?